SCHEMBL6136211

SCHEMBL6136211

CCN(C(=O)NCc1ccc(Cc2c(-c3ccc(O)cc3)ccc3cc(O)ccc23)cc1)c1cccc(Cl)c1C

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 2/20 0.38
▸ ESR2 Q92731 2/20 0.38
▸ MT-CO2 P00403 4/20 0.37
▸ ALDH2 P05091 4/20 0.33
▸ TRPV1 Q8NER1 2/20 0.33
▸ KMT2A Q03164 2/20 0.32
▸ HDAC1 Q13547 1/20 0.32
▸ HDAC6 Q9UBN7 1/20 0.32
▸ POLA1 P09884 1/20 0.32
▸ THRA P10827 1/20 0.32
▸ THRB P10828 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ MTOR P42345 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6136098 0.90 ESR1 (0.39) ESR1ESR2MT-CO2ALDH2TRPV1
SCHEMBL6136160 0.84 ESR1 (0.44) ESR1ESR2HDAC1HDAC6POLA1
SCHEMBL6136061 0.84 ESR1 (0.41) ESR1ESR2KMT2AHDAC1HDAC6
SCHEMBL6136130 0.83 ESR1 (0.41) ESR1ESR2KMT2AHDAC1HDAC6
SCHEMBL6136359 0.81 KMT2A (0.53) MT-CO2TRPV1KMT2AMEN1RAB9A
SCHEMBL6136113 0.79 TRPV1 (0.52) ESR1ESR2MT-CO2TRPV1KMT2A
SCHEMBL6136296 0.79 ESR1 (0.45) ESR1ESR2KMT2AHDAC1HDAC6
SCHEMBL6136101 0.78 ESR1 (0.46) ESR1ESR2TRPV1HDAC1HDAC6
SCHEMBL6136079 0.77 ESR1 (0.42) ESR1ESR2KMT2APOLA1MEN1
SCHEMBL6136025 0.77 TRPV1 (0.53) ESR1ESR2MT-CO2TRPV1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0895989-B1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity LILLY CO ELI (US) 2005-05-18 — — EP claimed
US-6509356-B1 Estrogen inhibitory activity method for the treatment of breast cancer in a woman comprising administering to a patient a therapeutically effective amount of a compound ELI LILLY AND COMPANY 2003-01-21 — — US claimed
WO-1999007377-A1 1-[4-(SUBSTITUTED ALKOXY)BENZYL]NAPHTHALENE COMPOUNDS HAVING ESTROGEN INHIBITORY ACTIVITY ELI LILLY AND COMPANY (US) 1999-02-18 — — WO claimed
EP-0895989-A1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity ELI LILLY AND COMPANY (US) 1999-02-10 — — EP claimed
EP-0895989-B1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity LILLY CO ELI (US) 2005-05-18 — — EP disclosed
US-6509356-B1 Estrogen inhibitory activity method for the treatment of breast cancer in a woman comprising administering to a patient a therapeutically effective amount of a compound ELI LILLY AND COMPANY 2003-01-21 — — US disclosed
WO-1999007377-A1 1-[4-(SUBSTITUTED ALKOXY)BENZYL]NAPHTHALENE COMPOUNDS HAVING ESTROGEN INHIBITORY ACTIVITY ELI LILLY AND COMPANY (US) 1999-02-18 — — WO disclosed
EP-0895989-A1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity ELI LILLY AND COMPANY (US) 1999-02-10 — — EP disclosed
Send feedback